알츠하이머병 치매 환자에서 도네페질(Donepezil)에 대한 최초 투약군과 전환군 간의 임상적 효용 비교 평가： 12개월 추적관찰 연구
Comparative Assessment of Clinical Efficacy between the Naive and the Switching Group to Donepezil：12 Months Prospective Study
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Objectives：The purpose of this study was to compare the efficacy between switching patients with Alzheimer’s disease (AD) from galantamine or rivastigmine to donepezil because they were not responding adequately, and naive patients with AD who initiated therapy with donepezil. Methods：A total of 108 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer’s Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients’ activities of daily living using Seoul-Activities of Daily Living (S-ADL) and the Seoul-Instrumental Activities of Daily Living (S-IADL)；behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial. Results：86 naive patients and 22 switching patients were enrolled in the study. 74 patients completed the study and 34 discontinued their treatment before week 52. There was no significant difference between two patient groups in demographic data, baseline characteristics and dementia severity except duration of illness. The total ADAS-cog-K scores were not significantly different from baseline after 52 weeks of treatment in both groups. Both groups demonstrated deterioration of S-ADL and S-IADL at 52 weeks. The NPI scores did not significantly change in both groups. Based on the operational criteria, 61.6% of the naive group and 54.5% of the switching group were responders to donepezil. Conclusion：The switching group had similar levels of efficacy with the naive group who initiated therapy with donepezil. These results suggest that patients not responding adequately to rivastigmine or galantamine may improve or stabilize after switching to donepezil and prior medication does not effect donepezil’s efficacy.
Abstract
Objectives：The purpose of this study was to compare the efficacy between switching patients with Alzheimer’s disease (AD) from galantamine or rivastigmine to donepezil because they were not responding adequately, and naive patients with AD who initiated therapy with donepezil. Methods：A total of 108 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer’s Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients’ activities of daily living using Seoul-Activities of Daily Living (S-ADL) and the Seoul-Instrumental Activities of Daily Living (S-IADL)；behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial. Results：86 naive patients and 22 switching patients were enrolled in the study. 74 patients completed the study and 34 discontinued their treatment before week 52. There was no significant difference between two patient groups in demographic data, baseline characteristics and dementia severity except duration of illness. The total ADAS-cog-K scores were not significantly different from baseline after 52 weeks of treatment in both groups. Both groups demonstrated deterioration of S-ADL and S-IADL at 52 weeks. The NPI scores did not significantly change in both groups. Based on the operational criteria, 61.6% of the naive group and 54.5% of the switching group were responders to donepezil. Conclusion：The switching group had similar levels of efficacy with the naive group who initiated therapy with donepezil. These results suggest that patients not responding adequately to rivastigmine or galantamine may improve or stabilize after switching to donepezil and prior medication does not effect donepezil’s efficacy.
참고문헌 (28)
- Doody RS, "Practice parameter: Management of dementia (an evidence based review)", Neurology, 56, pp.1154~1166 (2001)
- Santoro A, "Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study", CNS Drugs, 24, pp.163~176 (2010)
- Lanctôt KL, "Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis", CMAJ, 169, pp.557~564 (2003)
- Rogers SL, "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease", Neurology, 50, pp.136~145 (1998)
- Rosler M, "Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial", BMJ, 318, pp.633~638 (1999)
- Tariot PN, "A 5-month, randomized, placebo-controlled trial of galantamine in AD", Neurology, 54, pp.2269~2276 (2000)
- Gauthier S, "Strategies for continued successful treatment of Alzheimer’s disease:switching cholinesterase inhibitors", Curr Med Res Opin, 19, pp.707~714 (2003)
- Fava M, "Management of non-response and intolerance: switching strategies", J Clin Psychiatry, 61, pp.10~12 (2000)
- Auriacombe S, "Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil", Curr Med Res Opin, 18, pp.129~138 (2002)
- Ferris SH, "Switching previous therapies for Alzheimer’s disease to galantamine", Clin Ther, 23, pp.A3~7 (2001)
- Bartus RT, "The cholinergic hypothesis of geriatric memory dysfunction", Science, 217, pp.408~414 (1982)
- Cardozo MG, "QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase", J Med Chem, 35, pp.584~589 (1992)
- Rogers SL, "A 24-week,double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease", Neurology, 50, pp.136~145 (1998)
- Burns A, "The effects of donepezil in Alzheimer’s disease-results from a multinational trial", Dement Geriatr Cogn Disord, 10, pp.237~244 (1999)
- Mohs RC, "A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients", Neurology, 57, pp.481~488 (2001)
- Winblad B, "A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD", Neurology, 57, pp.489~495 (2001)
- McKhann G, "Clinical diagnosis of Alzheimer’s disease", Neurology, 34, pp.939~944 (1984)
- Kang YW, "A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- Korean Association for Geriatric Psychiatry, "Korean Assessment Scales for demented patients", pp.72~83 (2003), Hakji-Sa
- Rosen WG, "A new rating scale for Alzheimer’s disease", Am J Psychiatry, 141, pp.1356~1364 (1984)
- Ku HM, "A study on the reliability and validity of Seoul-Activities of Daily Living (SADL)", J Korean Geriatr Soc, 8, pp.206~214 (2004)
- 구형모, "일상활동평가-복합(Seoul-Instrumental Activities of Daily Living ; S-IADL)의 신뢰도 및 타당도 연구", 신경정신의학, 43(2), pp.189~199 (2004), 대한신경정신의학회
- Cummings JI, "The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia", Neurology, 44, pp.2308~2314 (1994)
- Choi SH, "The Korean version of the neuropsychiatric inventory: A scoring tool for neuropsychiatric disturbance in dementia patients", J Korean Med Sci, 15, pp.609~615 (2000)
- Winblad B, "Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success?", Int J Geriatr Psychiatry, 16, pp.653~666 (2001)
- Calabria M, "Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer’s disease: a 21-month follow-up real world study", Arch Gerontol Geriatr, 49, pp.e6~11 (2009)
- Gauthier S, "Efficacy of donepezil on behavioral symptoms in patients with moderate-to-severe Alzheimer’s disease", Int Psychogeriatr, 14, pp.389~404 (2002)
- Herrmann N, "Galantamine treatment of problematic behavior in Alzheimer’s disease", Am J Geriatr Psychiatry, 13, pp.527~534 (2005)